Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countries

Carmen de Keijzer, Jian-Yu E, Qian Yang, Robert Gitonga, David Hiller, Stephanie Jurgensen, Naji Salloum, Janete Cunha-Santos, Emmanuelle Hoogewys-Cynober, Laetitia Vinet, Magdalena Chirieac, Hadj Benzerdjeb, Daniela Thoene, Tjalf Ziemssen, Jiří Drahota, Dana Horáková, William Brown, Jeremy Hobart, Neil P. Robertson, Katja M. Hakkarainen, Sarah-Jo Sinnott

Therapeutic Advances in Neurological Disorders

Published online on May 22, 2026

Abstract

Therapeutic Advances in Neurological Disorders, Volume 19, January-December 2026.
Background:The European Union Summary of Product Characteristics (EU SmPC) for alemtuzumab in multiple sclerosis (MS) was revised in January 2020 under an Article 20 EU-pharmacovigilance procedure to include a revised indication, additional ...